ArticlesIrinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
Introduction
Standard therapy for metastatic colorectal cancer is fluorouracil, commonly modulated by calcium folinate, which typically yields a median survival time of 10–14 months.1, 2 Fluorouracil can be used as first-line or secondline therapy and a different regimen of fluorouracil can be administered as second-line treatment if first-line treatment fails. Survival time in these patients is typically short. Quality of life in patients receiving this treatment is generally poor.3, 4, 5, 6, 7, 8, 9, 10
Irinotecan inactivates topoisomerase I and thereby inhibits cell division.11, 12, 13 The drug has no cross-resistance with fluorouracil and functions via a novel molecular mechanism.14 Phase III studies of patients whose disease had not responded to first-line fluorouracil, or patients whose disease had progressed after first-line fluorouracil treatment, showed increased survival times in patients given irinotecan compared with those receiving best supportive care15 or high-dose fluorouracil and calcium folinate alone by continuous infusion.16 Data suggest that the development of well-tolerated regimens that combine irinotecan and high-dose fluorouracil and calcium folinate may be beneficial in the first-line treatment of colorectal cancer.
Phase I dose-escalation studies were done to test combined irinotecan with fluorouracil and calcium folinate weekly or every 2 weeks.17, 18 These regimens were selected for first-line treatment of advanced colorectal cancer, based on promising antitumour efficacy and an acceptable safety profile. The choice of regimen was left to investigators, according to local clinical practice, since the two regimens are widely used in Europe. The irinotecan combination and fluorouracil and calcium folinate alone were expected to differ by similar magnitudes in each regimen. Analysis of pooled data for efficacy showed that irinotecan gave a significant survival advantage.
We did a phase III multicentre randomised trial that was designed to assess whether the addition of irinotecan to fluorouracil and calcium folinate would benefit patients previously untreated with chemotherapy (other than adjuvant) for metastatic colorectal cancer.
Section snippets
Patients
From May, 1997, to February, 1998, we enrolled patients who met the following eligibility criteria: histologically proven adenocarcinoma of the colon or rectum; age 18–75 years; WHO performance status of 2 or less and life expectancy of more than 3 months; haemoglobin 100 g/L or more; absolute neutrophil count 2·0×10°/L; platelets 150×109/L or more; creatinine 1·25 or less times the upper limit of normal; total bilirubin 1·25 or less times the upper limit of normal; aspartate aminotransferase
Patients and treatment
387 patients were randomly assigned treatment. 385 patients received at least one infusion. Two patients received no study treatment because consent was withdrawn. Of the 385 patients treated in the study, only 97 (25%) received treatment by the weekly regimen (54 in the irinotecan group and 43 in the no-irinotecan group). The other 288 patients received treatment every 2 weeks (145 in the irinotecan group and 143 in the no-irinotecan group).
Baseline demographic and pretreatment characteristics
Discussion
Combination of irinotecan with fluorouracil and calcium folinate significantly increased response rates, time to progression, and survival. The survival advantage was reached, despite a higher proportion of patients receiving further chemotherapy in the no-irinotecan group (58·3 vs 39·4%).
This study population was large (385 patients treated), and the patients were representative of candidates for first-line chemotherapy in clinical practice, except that an unexpectedly high proportion of them
References (24)
- et al.
Protracted venous infusion of 5-fluorouracil and α-interferon in advanced and refractory colorectal cancer
Ann Oncol
(1994) - et al.
Topoisomerase-targetting antitumour drugs
Biochim Biophys Acta
(1989) - et al.
Topoisomerase I inhibitor: topotecan and irinotecan
Cancer Treat Rev
(1994) - et al.
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
Lancet
(1998) - et al.
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
Lancet
(1998) The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate
J Clin Oncol
(1992)- et al.
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomised trial in patients with advanced colorectal cancer
J Clin Oncol
(1998) - et al.
Tumour response and stabilization rates are worthwhile surrogate endpoints in metastatic colorectal cancer: analysis of data in 455 fluorouracil-resistant patients treated with irinotecan
Proc ASCO
(1997) - et al.
Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer
Cancer
(1994) - et al.
Clinical drug development: an analysis of phase II trials, 1970–1985
Cancer Treat Rep
(1987)
Weekly therapy with folinic acid (FA) and high dose fluorouracil (fluorouracil) 24 hour infusion in pretreated patients with metastatic colorectal carcinoma
Ann Oncol
High-dose 5-fluorouracil (fluorouracil) and folinic acid in advanced colorectal cancer resistant to standard dose fluorouracil treatment: results of a phase II study
Eur J Cancer
Cited by (3102)
Fighting colorectal cancer and its drug resistance with the resources of the flora of Africa
2024, Advances in Botanical ResearchChemotherapy-induced ileitis associated or not with colitis in digestive oncology patients: An AGEO multicentre study
2023, Digestive and Liver DiseaseColorectal liver metastases: Resect, ablate, or embolize
2023, Seminars in Colon and Rectal Surgery